In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Genocea Biosciences (NASDAQ: GNCA), with a price target of $2. The company’s shares closed yesterday at $0.66.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.9% and a 50.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Genocea Biosciences is a Moderate Buy with an average price target of $3.50, implying a 426.8% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $5 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.39 and a one-year low of $0.49. Currently, Genocea Biosciences has an average volume of 383.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.
